US researchers reveal positive results of personalised vaccine for liver cancer
Hepatocellular carcinoma is one of the leading causes of cancer-related deaths worldwide
Read More
Tag: hepatocellular carcinoma
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Updated analysis is from the Phase III IMbrave150 study
Read More
FDA green lights Opdivo, Yervoy combo for hepatocellular carcinoma
The combo has been granted Accelerated Approval in the US.
Read More
Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Read More
BMS’ Opdivo disappoints in late-stage trial
However, a clear trend was demonstrated towards improvement in overall survival.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
Stivarga final NICE recommendation for hepatocellular carcinoma
Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer.
Read More
US, EU filings for Eisai’s lenvatinib in liver cancer
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Read More
Priority review for BMS’ Opdivo in liver cancer
US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include to include certain patients with liver cancer.
Read More
Bayer files for expanded use of Stivarga in liver cancer
Bayer has filed applications in Europe, the US and Japan seeking approval to expand the scope of its cancer drug regorafenib to include the second-line treatment of liver cancer.
Read More
NICE rejects Bayer’s Nexavar for liver cancer
Bayer’s Nexavar is the latest medicine currently available through the Cancer Drugs Fund that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
